Taisho Pharmaceuticals | Sustainability Performance
Researches, develops, and markets pharmaceutical and healthcare products, focusing on over-the-counter drugs, prescription medicines, and wellness solutions.
1912
Japan
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Sustainability Ranking & Industry Benchmark
#6929
Overall#284
in Japan#161
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsB-corp & CDPFinancial Data
Business performanceCapital & innovation
Revenue
R&D intensity
Controversy level
- Taisho Pharmaceutical Holdings Co Ltd, Japanese major OTC pharma (LipovitanD, Bridgemark), has faced sustained class actions over the contested 2023 USD 4.7 billion Uehara familyled takeprivate (USD 4.7 billion deal, Japan's largest historic management buyout) affecting Japanese institutional minority shareholders, plus periodic Japanese MHLW enforcement on inadequate disclosure.
Revenue
EBITDA
Operating margin
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
6.9%FY2023
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
2.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
13%
Independent Directors
1 out of 8 incl. management
Overall score
71
Environment
99
Social
73
Governance
42
Exclusion screening
Adult content
Not available
Alcoholic
Available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
CDP Scores
Climate Score
Not disclosed
Water Score
Not disclosed
A
A-
B
B-
C
C-
D
D-
